András Váradi

András Váradi

Auto-generated profile, based on publicly available information

András Váradi

Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in FEBS Letters
Verified
Journal Article
Open access
PDF file
CTChristoph Thomas
Christoph Thomas
SAStephen Aller
Stephen Aller
KBKonstantinos Beis
Konstantinos Beis
ECElisabeth P. Carpenter
Elisabeth P. Carpenter
GCGeoffrey Chang
Geoffrey Chang
RTRobert Tampé
Robert Tampé
Members of the ATP‐binding cassette (ABC) transporter superfamily translocate a broad spectrum of chemically diverse substrates. While their eponymous ATP‐binding cassette in the nucleotide‐binding domains (NBDs) is highly conserved, their transmembrane domains (TMDs) forming the translocation pathway exhibit distinct folds and topologies, suggesting that during evolution the ancient motor domains were combined with different transmembrane mechanical systems to orchestrate a variety of cellular processes. In recent years, it has become increasingly evident that the distinct TMD folds are best suited to categorize the multitude of ABC transporters. We therefore propose a new ABC transporter classification that is based on structural homology in the TMDs.

12 July 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DDDóra Dedinszki
Dóra Dedinszki
Flora SzeriFlora Szeri
Flora Szeri
EKEszter Kozák
Eszter Kozák
VPViola Pomozi
Viola Pomozi
NTNatália Tőkési
Natália Tőkési
AVAndrás Váradi
András Váradi
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 April 2014 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
TÁTelbisz Ágnes
Telbisz Ágnes
CHCsilla Hegedüs
Csilla Hegedüs
AVAndrás Váradi
András Váradi
Balázs SarkadiBalázs Sarkadi
Balázs Sarkadi
CÖCsilla Özvegy-Laczka
Csilla Özvegy-Laczka
ABCG2 (ATP-binding cassette, subfamily G, member 2) is a plasma membrane glycoprotein that actively extrudes xenobiotics and endobiotics from the cells and causes multidrug resistance in cancer. In the liver, ABCG2 is expressed in the canalicular membrane of hepatocytes and excretes its substrates into the bile. ABCG2 is known to require high membrane cholesterol content for maximal activity, and by examining purified ABCG2 reconstituted in proteoliposomes we have recently shown that cholesterol is an essential activator, while bile acids significantly modify the activity of this protein. In the present work, by using isolated insect cell membrane preparations expressing human ABCG2 and its mutant variants, we have analyzed whether certain regions in this protein are involved in sterol recognition. We found that replacing ABCG2-R482 with large amino acids does not affect cholesterol dependence, but changes to small amino acids cause altered cholesterol sensitivity. When leucines in the potential steroid-binding element (SBE, aa 555–558) of ABCG2 were replaced by alanines, cholesterol dependence of ABCG2 activity was strongly reduced, although the L558A mutant variant when purified and reconstituted still required cholesterol for full activity. Regarding the effect of bile acids in isolated membranes, we found that these compounds decreased ABCG2-ATPase in the absence of drug substrates, which did not significantly affect substrate-stimulated ATPase activity. These ABCG2 mutant variants also altered bile acid sensitivity, although cholic acid and glycocholate were not transported by the protein. We suggest that the aforementioned two regions in ABCG2 are important for sterol sensing and may represent potential targets for pharmacologic modulation of ABCG2 function.

1 June 2016 in Current Opinion in Pharmacology
Verified
Journal Article
Open access
NRNabil A Rashdan
Nabil A Rashdan
FRFrank Rutsch
Frank Rutsch
Hervé KempfHervé Kempf
Hervé Kempf
AVAndrás Váradi
András Váradi
GLGeorges Lefthériotis
Georges Lefthériotis
VMVicky E. MacRae
Vicky E. MacRae
Connective tissue calcifying diseases (CTCs) are characterized by abnormal calcium deposition in connective tissues. CTCs are caused by multiple factors including chronic diseases (Type II diabetes mellitus, chronic kidney disease), the use of pharmaceuticals (e.g. warfarin, glucocorticoids) and inherited rare genetic diseases such as pseudoxanthoma elasticum (PXE), generalized arterial calcification in infancy (GACI) and Keutel syndrome (KTLS). This review explores our current knowledge of these rare inherited CTCs, and highlights the most promising avenues for pharmaceutical intervention. Advancing our understanding of rare inherited forms of CTC is not only essential for the development of therapeutic strategies for patients suffering from these diseases, but also fundamental to delineating the mechanisms underpinning acquired chronic forms of CTC.

17 November 2021 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
EKEszter Kozak
Eszter Kozak
KFKrisztina Fülöp
Krisztina Fülöp
NTNatália Tőkési
Natália Tőkési
NRNidhi Rao
Nidhi Rao
QLQiaoli Li
Qiaoli Li
VPViola Pomozi
Viola Pomozi

29 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EKEszter Kozak
Eszter Kozak
JBjonas bartstra
jonas bartstra
Pim de JongPim de Jong
Pim de Jong
Willem . P.Th.M MaliWillem . P.Th.M Mali
Willem . P.Th.M Mali
KFKrisztina Fülöp
Krisztina Fülöp
WSWilko Spiering
Wilko Spiering
Background: Pseudoxanthoma elasticum (PXE), a monogenic disorder resulting in calcification affecting the skin, eyes and peripheral arteries, is caused by mutations in the ABCC6 gene, and is associated with low plasma inorganic pyrophosphate (PPi). It is unknown how ABCC6 genotype affects plasma PPi. Methods: We studied the association of ABCC6 genotype (192 patients with biallelic pathogenic ABCC6 mutations) and PPi levels, and its association with the severity of arterial and ophthalmological phenotypes. ABCC6 variants were classified as truncating or non-truncating, and three groups of the 192 patients were formed: those with truncating mutations on both chromosomes (n = 121), those with two non-truncating mutations (n = 10), and a group who had one truncating and one non-truncating ABCC6 mutation (n = 61). The hypothesis formulated before this study was that there was a negative association between PPi level and disease severity. Results: Our findings confirm low PPi in PXE compared with healthy controls (0.53 ± 0.15 vs. 1.13 ± 0.29 µM, p < 0.01). The PPi of patients correlated with increasing age (β: 0.05 µM, 95% CI: 0.03–0.06 per 10 years) and was higher in females (0.55 ± 0.17 vs. 0.51 ± 0.13 µM in males, p = 0.03). However, no association between PPi and PXE phenotypes was found. When adjusted for age and sex, no association between PPi and ABCC6 genotype was found. Conclusions: Our data suggest that the relationship between ABCC6 mutations and reduced plasma PPi may not be as direct as previously thought. PPi levels varied widely, even in patients with the same ABCC6 mutations, further suggesting a lack of direct correlation between them, even though the ABCC6 protein-mediated pathway is responsible for ~60% of this metabolite in the circulation. We discuss potential factors that may perturb the expected associations between ABCC6 genotype and PPi and between PPi and disease severity. Our findings support the argument that predictions of pathogenicity made on the basis of mutations (or on the structure of the mutated protein) could be misleading.